MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-12-2026
Prelude Therapeutics Incorporated EV - Enterprise Value 2011-2026 | PRLD
Annual EV - Enterprise Value Prelude Therapeutics Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 314 M | 304 M | 226 M | 300 M | 394 M | 579 K | 71.3 M | 39.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 394 M | 579 K | 206 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
4.15 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
6.3 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-4.92 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
686 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
5.18 B | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
-5.73 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
1.16 B | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
599 M | $ 32.59 | -6.89 % | $ 877 M | USA |
|
Forte Biosciences
FBRX
|
280 M | $ 21.59 | -1.86 % | $ 280 M | USA |
 |
Affimed N.V.
AFMD
|
-38.5 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
11.4 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-1.83 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
115 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
68.7 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
23.6 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | USA |
 |
BioNTech SE
BNTX
|
17.1 B | $ 92.14 | 1.33 % | $ 22.3 B | Germany |
 |
Grifols, S.A.
GRFS
|
16.3 B | $ 7.98 | -1.6 % | $ 5.42 B |  Spain |
 |
Akouos
AKUS
|
107 M | - | 0.23 % | $ 488 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
629 M | $ 1.7 | 3.03 % | $ 452 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | Israel |
 |
Heron Therapeutics
HRTX
|
411 M | $ 0.86 | -1.42 % | $ 143 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-2.16 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
248 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
-1.17 B | - | - | $ 3.37 B | China |
 |
Compugen Ltd.
CGEN
|
106 M | $ 2.8 | 7.28 % | $ 262 M | Israel |
 |
Anika Therapeutics
ANIK
|
156 M | $ 14.88 | -0.93 % | $ 213 M | USA |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Incyte Corporation
INCY
|
18.2 B | $ 97.16 | -0.26 % | $ 19 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
15.6 B | $ 75.56 | -0.29 % | $ 12.1 B | USA |
 |
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.35 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-721 K | $ 3.4 | -1.16 % | $ 5.6 M | Israel |
 |
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
335 M | $ 1.61 | 2.55 % | $ 189 M | USA |
 |
Albireo Pharma
ALBO
|
426 M | - | -0.23 % | $ 916 M | USA |